SERB will present in vivo data for a polyclonal antibody in development as an antidote for ricin poisoning, on the first day of the upcoming NACCT in Montreal.

West Conshohocken, PA, 13 July 2023: SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard® (uridine triacetate) and Xuriden® (uridine triacetate), from Wellstat Therapeutics. Both medicines are commercially available in the US and currently distributed across Europe on a named patient or compassionate use basis.  Jeremie Urbain, […]

West Conshohocken, PA, 22 June 2023:  BTG Pharmaceuticals, a SERB company, highlights the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Acute Lymphoblastic Leukemia, B-Cell Lymphomas, Pediatric Acute Lymphoblastic Leukemia, and Pediatric Aggressive Mature B-Cell Lymphomas. i-iv The updated guidelines: “The updated guidelines will help ensure that healthcare professionals understand the current […]